Evaxion Biotech (EVAX) has released an update.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Evaxion Biotech has unveiled promising preclinical results for its cytomegalovirus vaccine program, EVX-V1, utilizing its AI-Immunology platform to trigger targeted immune responses. The innovative approach, which combines AI-identified antigens with a proprietary prefusion glycoprotein B antigen, marks a significant step towards developing an effective CMV vaccine. This development could potentially tap into the growing CMV treatment market, valued at $474.6 million in 2023, and poised for further growth.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.